Humana Inc (NYSE:HUM) has received an average recommendation of “Buy” from the twenty brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $338.11.
HUM has been the topic of several recent analyst reports. Barclays set a $24.00 target price on shares of Tenet Healthcare and gave the stock a “hold” rating in a report on Wednesday, April 17th. SunTrust Banks lifted their target price on shares of Markel to $1,100.00 and gave the stock a “hold” rating in a report on Thursday, May 2nd. ValuEngine upgraded shares of Valmont Industries from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research lowered shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Finally, Oppenheimer decreased their price target on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd.
Institutional investors have recently modified their holdings of the company. Stephens Inc. AR boosted its position in shares of Humana by 48.5% during the 4th quarter. Stephens Inc. AR now owns 1,369 shares of the insurance provider’s stock valued at $392,000 after acquiring an additional 447 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Humana by 6,493.6% during the 1st quarter. Pacer Advisors Inc. now owns 12,396 shares of the insurance provider’s stock valued at $3,298,000 after acquiring an additional 12,208 shares in the last quarter. Machina Capital S.A.S. acquired a new stake in shares of Humana during the 4th quarter valued at about $809,000. World Asset Management Inc boosted its position in shares of Humana by 10.9% during the 1st quarter. World Asset Management Inc now owns 10,840 shares of the insurance provider’s stock valued at $2,883,000 after acquiring an additional 1,067 shares in the last quarter. Finally, Kinneret Advisory LLC acquired a new stake in shares of Humana during the 4th quarter valued at about $1,031,000. Institutional investors and hedge funds own 92.61% of the company’s stock.
HUM traded up $11.06 during trading on Tuesday, hitting $291.25. The stock had a trading volume of 2,058,846 shares, compared to its average volume of 1,139,136. The stock has a market capitalization of $39.33 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 1.20 and a beta of 0.87. Humana has a 12 month low of $225.65 and a 12 month high of $355.88. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40. The company has a 50 day simple moving average of $258.65.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping the consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion for the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.36 EPS. As a group, research analysts forecast that Humana will post 17.48 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.55 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $2.20 annualized dividend and a yield of 0.76%. Humana’s dividend payout ratio is 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.